Pomegra
UK-founded diagnostic booking platform Scan.com closes $90M Series C equity and $130M in debt to accelerate US expansion after doubling annualized revenue to $165M.
- Scan.com raised $90M equity led by Noteus Partners, with Aviva and Oxford Capital joining; $130M in debt adds firepower for US acquisitions.
- Revenue doubled year-over-year to a $165M annualized run rate, with more than 900,000 patients served across its global network.
- The company is now in pre-IPO positioning, with reported meetings at the London Stock Exchange signaling a potential public offering on the horizon.
Lead
Scan.com, the UK-based platform for booking outpatient diagnostic scans, announced on August 31, 2026, that it has closed $220 million in combined financing - a $90 million Series C equity round led by Noteus Partners, alongside a $130 million debt facility provided by VerisFi Capital and Atempo Growth. Aviva, Concord Health Partners, YZR Capital, and Oxford Capital joined the equity tranche. The capital is earmarked almost entirely for the United States, where the company is racing to build what it describes as the country's largest diagnostic imaging network.
What Scan.com Actually Does
The company started as a marketplace connecting patients in the UK to private MRI, CT, and ultrasound appointments - cutting waiting times by routing bookings to underutilized scanner capacity at private clinics. It has since built an API layer that integrates with electronic medical records, enabling clinicians to order and schedule scans directly within their existing systems. That B2B2C positioning is what separates it from a simple booking tool and is the core pitch to hospital systems and insurers in the US market. Over 900,000 patients globally have used the platform to access care.
Why Does the Capital Stack Matter?
The structure of this deal is worth reading carefully. The $90 million equity round is the headline, but the $130 million debt facility is where the acquisition strategy lives. Scan.com has signaled plans for targeted purchases of regional imaging scheduling networks across the US - the kind of bolt-on buying that requires debt rather than dilutive equity. Stacking debt on top of fresh equity gives the company flexibility to move fast on deals without repricing its cap table.
What it also implies: investors at this round are pricing the company at a premium to its $165 million annualized run rate, a figure that doubled over the past twelve months. No post-money valuation has been disclosed, but a revenue multiple in line with comparable health-tech platforms would put the number well north of $300 million. The company has not confirmed a figure.
What Comes Next for Scan.com's US Push?
The US diagnostic imaging market is large, fragmented, and structurally ripe for a platform play. Independent imaging centers have limited digital infrastructure and high patient no-show rates - exactly the friction a scheduling API solves. Scan.com's expansion strategy combines organic network-building with acquisitions of smaller scheduling operators, with its new agentic AI layer designed to route patients to the nearest available slot in real time.
The IPO signal is also hard to ignore. Reports indicate Scan.com representatives have met with officials at the London Stock Exchange, a customary step in pre-IPO preparation. At a $165 million run rate - and growing - the company is approaching the revenue threshold where a public offering becomes a credible near-term option, rather than a distant aspiration.
The core risk remains execution. Building a national US imaging network through acquisition is slow and operationally complex. Regulatory approvals, integration of disparate booking systems, and insurance credentialing all create friction that momentum alone cannot overcome. Scan.com will be tested on whether its platform can absorb acquired networks without degrading the patient experience that drove its growth in the first place.
Outlook
Scan.com enters the back half of 2026 with a fortified balance sheet and a clear geographic mandate. The $90 million equity round - with Noteus Partners at the helm and Aviva adding institutional weight - validates the platform thesis at meaningful scale. The $130 million debt tranche signals acquisitive intent. Whether the company can convert that capital into a defensible US market position before better-funded competitors close the gap is the question that will define its IPO story, whenever that comes.
